Evidence map›Paper›PMID 37570714›Full record

ArticleMolecules (Basel, Switzerland)2023

Identification of the Microbial Transformation Products of Secoisolariciresinol Using an Untargeted Metabolomics Approach and Evaluation of the Osteogenic Activities of the Metabolites.

Wen-Xuan Yu, Hok-Him Tang, Jun-Jie Ye, Hui-Hui Xiao, Chung-Yan Lam, Tim-Fat Shum, Zhi-Kang Sun, Yuan-Zhen Li, Xin-Yu Zang, Wen-Chao Du and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Wen-Xuan YuDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
Hok-Him TangDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
Jun-Jie YeIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Hui-Hui XiaoDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.ORCID 0000-0001-7501-7112
Chung-Yan LamDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
Tim-Fat ShumDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.ORCID 0000-0002-4149-2983
Zhi-Kang SunIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Yuan-Zhen LiIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Xin-Yu ZangIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Wen-Chao DuIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Jian-Ping ZhangIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Tsz-Hung KongDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
Li-Ping ZhouResearch Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
Jia-Chi ChiouDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.ORCID 0000-0001-8306-1826
Chun-Fai KungIncreasepharm (HK) Limited, Hong Kong Science Park, Shatin, Hong Kong, China.
Kam-Wah MokDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.ORCID 0000-0002-6677-2949
Jing HuIncreasepharm (Tianjin) Innovative Medicine Institute Limited, Tianjin 300382, China.
Man-Sau WongDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.ORCID 0000-0002-0729-8618
Hong Kong Polytechnic University · HKHong Kong Science and Technology Parks Corporation · HK

Funding

Mainland-Hong Kong Joint Funding Scheme ITF-MOST:MHX/002/20National Key R&D Program of China 2021YFE0202100
6 · The paper itself

Abstract

Secoisolariciresinol (SECO) is one of the major lignans occurring in various grains, seeds, fruits, and vegetables. The gut microbiota plays an important role in the biotransformation of dietary lignans into enterolignans, which might exhibit more potent bioactivities than the precursor lignans. This study aimed to identify, synthesize, and evaluate the microbial metabolites of SECO and to develop efficient lead compounds from the metabolites for the treatment of osteoporosis. SECO was fermented with human gut microbiota in anaerobic or micro-aerobic environments at different time points. Samples derived from microbial transformation were analyzed using an untargeted metabolomics approach for metabolite identification. Nine metabolites were identified and synthesized. Their effects on cell viability, osteoblastic differentiation, and gene expression were examined. The results showed that five of the microbial metabolites exerted potential osteogenic effects similar to those of SECO or better. The results suggested that the enterolignans might account for the osteoporotic effects of SECO in vivo. Thus, the presence of the gut microbiota could offer a good way to form diverse enterolignans with bone-protective effects. The current study improves our understanding of the microbial transformation products of SECO and provides new approaches for new candidate identification in the treatment of osteoporosis.

Indexed as

4-ButyrolactoneLignansButylene GlycolsDietHumans4-ButyrolactoneButylene GlycolsLignanssecoisolariciresinolmetabolitesmicrobial transformationosteogenic activitiessecoisolariciresinol

Identifiers

PMID37570714
PMCPMC10420892
OpenAlexW4385421872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.